Literature DB >> 30206711

Correlation between magnetic resonance imaging (MRI) findings and the new bone formation factor Dkk-1 in patients with spondyloarthritis.

Zheng Zhao1, Gang Wang1, Yanyan Wang1, Jinshui Yang1, Yiwen Wang1, Jian Zhu1, Feng Huang2.   

Abstract

In recent years, MRI has been regarded as a major diagnostic tool for spondyloarthritis (SpA), and anti-TNF therapy has been widely confirmed as an effective treatment strategy. This study was designed to investigate the correlation between the secreted protein dickkopf-1 (Dkk-1) and abnormal findings on magnetic resonance imaging (MRI) through a prospective study of 30 cases of SpA. Thirty patients with active SpA were included, all treated with recombinant human tumor necrosis factor (TNF) receptor-antibody fusion protein (YiSaiPu) injection at 50 mg/week for 6 months. All patients were also examined for their clinical, serological, and imaging manifestations of the condition before and after treatment. In patients receiving TNF inhibitor treatment, the erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and clinical activity indices BASDAI, BASFI, BASMI, ASDAS-CRP were significantly decreased (p < 0.01). Serum Dkk-1 concentration was also significantly decreased (p < 0.05), as were the scores of bone marrow edema of the sacroiliac joints and the spine (p < 0.05). The score of sacroiliac joint backfill was significantly increased (p < 0.05), and the baseline and changes in the serum Dkk-1 concentration were significantly correlated with the baseline and changes in spinal bone marrow edema levels. Inhibition of the level of serum Dkk-1 by TNF inhibitors may be the molecular basis for inhibiting the formation of new bone in SpA patients. In addition, spinal marrow edema may have significance for predicting new bone formation.

Entities:  

Keywords:  Dkk-1; Magnetic resonance imaging (MRI); Spondyloarthritis (SpA); TNF inhibitors

Mesh:

Substances:

Year:  2018        PMID: 30206711     DOI: 10.1007/s10067-018-4284-y

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  14 in total

1.  Etanercept in adult patients with early onset ankylosing spondylitis.

Authors:  Robert D Inman; Daniel O Clegg; John C Davis; James B Whitmore; Alan Solinger
Journal:  J Rheumatol       Date:  2006-08       Impact factor: 4.666

2.  Knocking down dickkopf-1 alleviates estrogen deficiency induction of bone loss. A histomorphological study in ovariectomized rats.

Authors:  Feng-Sheng Wang; Jih-Yang Ko; Chun-Liang Lin; Hsing-Long Wu; Huei-Jin Ke; Pei-Ju Tai
Journal:  Bone       Date:  2006-10-20       Impact factor: 4.398

3.  Development and preliminary validation of the spondyloarthritis research consortium of Canada magnetic resonance imaging sacroiliac joint structural score.

Authors:  Walter P Maksymowych; Stephanie Wichuk; Praveena Chiowchanwisawakit; Robert G Lambert; Susanne J Pedersen
Journal:  J Rheumatol       Date:  2014-10-15       Impact factor: 4.666

Review 4.  Dickkopf-1 as a potential therapeutic target in Paget's disease of bone.

Authors:  Helen S McCarthy; Michael J Marshall
Journal:  Expert Opin Ther Targets       Date:  2010-02       Impact factor: 6.902

5.  Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.

Authors:  A Calin; B A C Dijkmans; P Emery; M Hakala; J Kalden; M Leirisalo-Repo; E M Mola; C Salvarani; R Sanmartí; J Sany; J Sibilia; J Sieper; S van der Linden; E Veys; A M Appel; S Fatenejad
Journal:  Ann Rheum Dis       Date:  2004-09-02       Impact factor: 19.103

6.  Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis.

Authors:  Xenofon Baraliakos; Hildrun Haibel; Joachim Listing; Joachim Sieper; Jürgen Braun
Journal:  Ann Rheum Dis       Date:  2013-03-16       Impact factor: 19.103

7.  Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis.

Authors:  Rik J U Lories; Inge Derese; Cosimo de Bari; Frank P Luyten
Journal:  Arthritis Rheum       Date:  2007-02

8.  Increase in Dickkopf-1 Serum Level in Recent Spondyloarthritis. Data from the DESIR Cohort.

Authors:  Gaetane Nocturne; Stephan Pavy; Saida Boudaoud; Raphaèle Seror; Philippe Goupille; Philippe Chanson; Désirée van der Heijde; Floris van Gaalen; Francis Berenbaum; Xavier Mariette; Karine Briot; Antoine Feydy; Pascal Claudepierre; Philippe Dieudé; Joanne Nithitham; Kimberly E Taylor; Lindsey A Criswell; Maxime Dougados; Christian Roux; Corinne Miceli-Richard
Journal:  PLoS One       Date:  2015-08-27       Impact factor: 3.240

9.  The FAt Spondyloarthritis Spine Score (FASSS): development and validation of a new scoring method for the evaluation of fat lesions in the spine of patients with axial spondyloarthritis.

Authors:  Susanne Juhl Pedersen; Zheng Zhao; Robert G W Lambert; Stephanie Wichuk; Mikkel Østergaard; Ulrich Weber; Walter P Maksymowych
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

10.  Inflammatory and structural changes in vertebral bodies and posterior elements of the spine in axial spondyloarthritis: construct validity, responsiveness and discriminatory ability of the anatomy-based CANDEN scoring system in a randomised placebo-controlled trial.

Authors:  Susanne J Pedersen; Mikkel Østergaard; Simon Krabbe; Inge J Sørensen; Bente Jensen; Jakob M Møller; Lone Balding; Ole R Madsen; Robert G W Lambert; Walter P Maksymowych
Journal:  RMD Open       Date:  2018-03-16
View more
  4 in total

Review 1.  Effects of targeted therapies on bone in rheumatic and musculoskeletal diseases.

Authors:  Harjit P Bhattoa; Zoltán Szekanecz; Boglárka Soós; Ágnes Szentpétery; Hennie G Raterman; Willem F Lems
Journal:  Nat Rev Rheumatol       Date:  2022-03-10       Impact factor: 20.543

Review 2.  Wnt Signaling and Biological Therapy in Rheumatoid Arthritis and Spondyloarthritis.

Authors:  Daniela Cici; Addolorata Corrado; Cinzia Rotondo; Francesco P Cantatore
Journal:  Int J Mol Sci       Date:  2019-11-07       Impact factor: 5.923

3.  Vitronectin-derived bioactive peptide prevents spondyloarthritis by modulating Th17/Treg imbalance in mice with curdlan-induced spondyloarthritis.

Authors:  Hong Ki Min; JeongWon Choi; Seon-Yeong Lee; A Ram Lee; Byung-Moo Min; Mi-La Cho; Sung-Hwan Park
Journal:  PLoS One       Date:  2022-01-05       Impact factor: 3.240

Review 4.  Practical Significance of Biomarkers in Axial Spondyloarthritis: Updates on Diagnosis, Disease Activity, and Prognosis.

Authors:  Alexandra-Diana Diaconu; Alexandr Ceasovschih; Victorița Șorodoc; Cristina Pomîrleanu; Cătălina Lionte; Laurențiu Șorodoc; Codrina Ancuța
Journal:  Int J Mol Sci       Date:  2022-09-30       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.